

AMENDMENTS TO THE CLAIMS

1. (**Currently Amended**) Supplement preparation for therapeutic treatment of infectious diseases in animals ~~including human beings~~ on a daily basis by ingestion including:

a) a first active component in form of a therapeutically effective amount of biologically accessible silver in an amount of 0.5 – 50 mg of biologically accessible silver per litre preparation, and

b) a second active component of cartilage, and

c) any conventional additives,

wherein the weight ratio of a:b is between 1:100,000 and 1:10.

2. (Previously Presented) Preparation according to claim 1, wherein it includes one or more additional active components.

3. (Previously Presented) Preparation according to claim 2, wherein it includes one or more additional active components selected among antimony pentasulphide, metallic tin and/or a tin salt, metallic zinc and/or a zinc salt, a sulphur containing substance and/or a iodine containing substance.

4. (Previously Presented) Preparation according to claim 3, including hepar sulphuris as a sulphur containing substance.

5. (Previously Presented) Preparation according to claim 3, including tare powder as a iodine containing substance.

6. (Previously Presented) Preparation according to claim 1, wherein the first active component (a) is a colloidal silver.

7. (Previously Presented) Preparation according to claim 1, wherein the second active component (b) is ground and/or dried cartilage.

8. (Previously Presented) Preparation according to claim 1, wherein the second active component (b) is obtained from a cartilaginous fish.

9. (Previously Presented) Preparation according to claim 1, wherein the content of cartilage, calculated as dry matter, is 100 - 12,000 parts by weight per 1 part by weight of biologically accessible silver.

10. (Cancelled)

11. **(Currently Amended)** A method for health-promoting treatment of infectious diseases for animals ~~including human beings~~ by daily treatment with a preparation comprising:
adding to animal feed or drinking water the preparation including:
(a) a first active component in form of a therapeutically effective amount of biologically accessible silver in an amount of 0.5 – 50 mg of biologically accessible silver per litre preparation; and
(b) a second active component of cartilage, and
(c) any additional active components and/or conventional accessory agents or additives,
wherein the weight ratio of a:b is between 1:100,000 and 1:10; and
ingesting the preparation.

12. **(Previously Presented)** The method according to claim 11, wherein the preparation is used for prevention and treatment of plasmacytosis, mink distemper virus, enteritis virus and/or “sticky” kits in mink.

13. – 21. **(Cancelled)**

22. **(New)** The preparation according to claim 1, wherein said animal is a mink or a human.

23. **(New)** The preparation according to claim 11, wherein said animal is a mink or a human.